亚太新兴感染疾病诊断市场 - 分析与预测（2023-2033）

Asia-Pacific Emerging Infectious Disease Diagnostics Market - Analysis and Forecast, 2023-2033

出版日期: 2023年12月01日 | 出版商:

BIS Research | 英文 116 Pages | 商品交期: 1-5个工作天内

价格

简介目录图表

亚太新兴感染疾病诊断市场2022年估值为44.1亿美元，预计到2033年将达到108.3亿美元，2023年至2033年年复合成长率为8.65%。预计这将会发生。

推动亚太地区感染疾病诊断市场扩张的因素很多。其中包括感染疾病的经济负担、政府以伙伴关係和融资形式提供的支持、对快速彻底检测的需求增加以及分子诊断技术的进步。

主要市场统计数据
预测期	2023-2033
2023年评估价值	47.3亿美元
2033年预测	108.3亿美元
年复合成长率	8.65%

在亚太市场，感染疾病诊断包括用于识别和发现潜在感染者中的传染源的各种方法和程序。这些诊断对于快速治疗决策、准确的疾病诊断和公共卫生倡议的实施至关重要。

微生物培养是诊断感染疾病的基本方法之一。病患检体在特殊的生长培养基中培养，以分离和鑑定特定的病原体。这使得医疗保健专业人员能够识别致病细菌并评估抗生素敏感性。

分子诊断是亚太产业的关键策略。这涉及使用核酸增幅检查（NAAT）和聚合酶链反应（PCR）等方法检测传染源的基因组成。即使在低浓度下，这也可以特异性识别病原体。

本报告调查了亚太地区新兴的感染疾病诊断市场，提供了市场概述以及应用、技术、感染类型、疾病类型、最终用户、地区和进入市场的公司的趋势。我们提供概况和更多的。

Introduction to Asia-Pacific Emerging Infectious Disease Diagnostics Market

The Asia-Pacific emerging infectious disease diagnostics market was valued at $4.41 billion in 2022 and is expected to reach $10.83 billion by 2033, growing at a CAGR of 8.65% between 2023 and 2033. A number of factors are driving the growing infectious disease diagnostics market's expansion in the Asia-Pacific area. The financial burden of infectious diseases, support from governments in the form of partnerships and financing, the growing demand for rapid and thorough testing, and developments in molecular diagnostics technology are some of these causes.

Market Introduction

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$4.73 Billion
2033 Forecast	$10.83 Billion
CAGR	8.65%

In the APAC market, diagnostics for infectious diseases comprise a variety of approaches and procedures used to identify and find infectious agents in people who may be infected. These diagnostics are essential for prompt treatment decisions, accurate disease diagnosis, and the execution of public health initiatives.

Microbiological culture is one of the basic methods used in the diagnosis of infectious diseases. To isolate and identify certain pathogens, patient specimens are cultured on specialized growth media. Healthcare professionals can identify the causing organism and evaluate its antibiotic susceptibility by doing this.

Molecular diagnostics is a key strategy in the APAC industry. This entails detecting the genetic makeup of the infectious pathogen using methods like nucleic acid amplification tests (NAATs) and polymerase chain reaction (PCR). This enables the highly sensitive and specific identification of pathogens, even at low concentrations.

Market Segmentation:

Segmentation 1: by Application

Laboratory Testing
Point-of-Care Testing

Segmentation 2: by Technology

Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Next-Generation Sequencing (NGS)
Immunodiagnostics
Other Technologies

Segmentation 3: by Type of Infection

Bacterial
Viral
Fungal
Other Infections

Segmentation 4: by Disease Type

Respiratory Infections
Sexually Transmitted Infections (STIs)
Gastrointestinal Infections
Other Infections

Segmentation 5: by End User

Hospitals and Clinics
Diagnostic Laboratories
Other End Users

Segmentation 6: by Region

Asia-Pacific - Japan, China, India, South Korea, Australia, Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Asia-Pacific emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Asia-Pacific emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the Asia-Pacific emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

1 Markets

1.1 Market Outlook
- 1.1.1 Product Definition
- 1.1.2 Inclusion and Exclusion Criteria
- 1.1.3 Key Findings
1.2 Industry Outlook
- 1.2.1 Market Overview
  - 1.2.1.1 Timeline of Emerging Technologies for Infectious Disease Diagnostics
  - 1.2.1.2 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
  - 1.2.1.3 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
  - 1.2.1.4 Current Market Landscape of Emerging Infectious Disease Diagnostics
  - 1.2.1.5 Future Potential
    - 1.2.1.5.1 CRISPR
    - 1.2.1.5.2 NGS
    - 1.2.1.5.3 INAAT
    - 1.2.1.5.4 Digital PCR (dPCR)
- 1.2.2 Patent Analysis
  - 1.2.2.1 By Year
  - 1.2.2.2 By Country/Organization
- 1.2.3 Pipeline Analysis
- 1.2.4 Impact of COVID-19 on Infectious Disease Diagnostics
  - 1.2.4.1 Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
- 1.2.5 Supply Chain Analysis
1.3 Market Dynamics
- 1.3.1 Impact Analysis
- 1.3.2 Drivers
  - 1.3.2.1 Economic Burden of Infectious Diseases
  - 1.3.2.2 Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
  - 1.3.2.3 Increasing Demand for Point-of-Care (POC) and Syndromic Testing
  - 1.3.2.4 Technological Advancements in Molecular Diagnostics
    - 1.3.2.4.1 Isothermal Nucleic Acid Amplification Techniques (INAATs)
    - 1.3.2.4.2 Digital PCR
    - 1.3.2.4.3 CRISPR Technologies
- 1.3.3 Restraints
  - 1.3.3.1 Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
  - 1.3.3.2 Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
  - 1.3.3.3 Lack of an Established Framework for NGS-based Tests for Infectious Diseases
- 1.3.4 Opportunities
  - 1.3.4.1 Potential of Molecular Diagnostic Tests in Low-Resource Settings
  - 1.3.4.2 Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance

2 Asia-Pacific

2.1 Asia-Pacific Emerging Infectious Disease Diagnostics Market
- 2.1.1 Regulatory Framework
- 2.1.2 Market Dynamics
  - 2.1.2.1 Impact Analysis
- 2.1.3 Market Size and Forecast
  - 2.1.3.1 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Application)
  - 2.1.3.2 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Technology)
  - 2.1.3.3 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Type of Infection)
  - 2.1.3.4 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Disease Type)
  - 2.1.3.5 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User)
  - 2.1.3.6 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Country)
    - 2.1.3.6.1 Japan
      - 2.1.3.6.1.1 Market Dynamics
      - 2.1.3.6.1.2 Market Size and Forecast
      - 2.1.3.6.1.2.1 Japan Emerging Infectious Disease Diagnostics Market (by End User)
    - 2.1.3.6.2 China
      - 2.1.3.6.2.1 Market Dynamics
      - 2.1.3.6.2.2 Market Size and Forecast
      - 2.1.3.6.2.2.1 China Emerging Infectious Disease Diagnostics Market (by End User)
    - 2.1.3.6.3 Australia
      - 2.1.3.6.3.1 Market Dynamics
      - 2.1.3.6.3.2 Market Size and Forecast
      - 2.1.3.6.3.2.1 Australia Emerging Infectious Disease Diagnostics Market (by End User)
    - 2.1.3.6.4 South Korea
      - 2.1.3.6.4.1 Market Dynamics
      - 2.1.3.6.4.2 Market Size and Forecast
      - 2.1.3.6.4.2.1 South Korea Emerging Infectious Disease Diagnostics Market (by End User)
    - 2.1.3.6.5 India
      - 2.1.3.6.5.1 Market Dynamics
      - 2.1.3.6.5.2 Market Size and Forecast
      - 2.1.3.6.5.2.1 India Emerging Infectious Disease Diagnostics Market (by End User)
    - 2.1.3.6.6 Rest-of-Asia-Pacific
      - 2.1.3.6.6.1 Market Dynamics
      - 2.1.3.6.6.2 Market Size and Forecast
      - 2.1.3.6.6.2.1 Rest-of-Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User)

3 Markets - Competitive Benchmarking & Company Profiles

3.1 Competitive Landscape
- 3.1.1 Overview
- 3.1.2 Corporate Strategies
  - 3.1.2.1 Mergers and Acquisitions
  - 3.1.2.2 Synergistic Activities
  - 3.1.2.3 Business Expansions and Funding
- 3.1.3 Business Strategies
  - 3.1.3.1 Product Launches/Upgradations/Approvals
3.2 Market Share Analysis
3.3 Emerging Infectious Disease Diagnostics Ecosystem Active Players
3.4 Company Profiles
3.5 Company Snapshots
- 3.5.1 CrisprBits
  - 3.5.1.1 Company Overview
  - 3.5.1.2 Role of CrisprBits in the Emerging Infectious Disease Diagnostics Market
  - 3.5.1.3 Key Developments

简介目录图表

List of Figures

Figure 1: History of Infectious Disease Outbreaks Globally
Figure 2: Number of Infectious Disease Outbreaks per Year Reported by the WHO, Estimates
Figure 3: Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 4: Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 5: Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 6: Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 7: Share of Key Developments, January 2019-June 2023
Figure 8: Emerging Infectious Disease Diagnostics Market (by Region), $Billion, 2022 and 2033
Figure 9: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 10: Key Insights Validated from Primary Interviews
Figure 11: Emerging Infectious Disease Diagnostics Market Segmentation
Figure 12: Emerging Infectious Disease Diagnostics Market Research Methodology
Figure 13: Primary Research Methodology
Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
Figure 15: Top-Down Approach (Segment-Wise Analysis)
Figure 16: Timeline of Emerging Technologies for Infectious Disease Diagnostics
Figure 17: Advantages of Emerging Infectious Disease Diagnostic Technologies
Figure 18: Limitations of Emerging Infectious Disease Diagnostic Technologies
Figure 19: Key Settings of POC Testing Deployment
Figure 20: Key Challenges Associated with Point-of-Care Testing
Figure 21: Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 22: Future Potential of NGS in Infectious Disease Diagnostics
Figure 23: Number of Molecular Diagnostics Patents for Infectious Diseases (by Year)
Figure 24: Number of Molecular Diagnostic Patents for Infectious Diseases (by Country/Organization)
Figure 25: Key Benefits of Home-Based Testing
Figure 26: Typical Supply Chain for a Diagnostic Test
Figure 27: Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 28: Fiscal Response to the COVID-19 Pandemic (% of GDP)
Figure 29: Advantages of Point-of-Care Tests in Molecular Diagnostics
Figure 30: Key Clinical Areas Demanding Commercial Availability of Syndromic Tests
Figure 31: Advantages of INAAT over PCR
Figure 32: Number of LAMP Publications on Public Databases, 2016-2022
Figure 33: Number of INAAT Publications on Public Databases, 2016-2022
Figure 34: Advantages of Digital PCR over Quantitative Real-Time PCR
Figure 35: Number of "Digital PCR" Publications on Public Databases, 2016-2022
Figure 36: Notable Outbreaks of Infectious Diseases in Humans (by Region)
Figure 37: Number of Infectious Disease Outbreaks per Year Reported by the WHO, Estimates
Figure 38: Asia-Pacific Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 39: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 40: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 41: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
Figure 42: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
Figure 43: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 44: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 45: Japan Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 46: Japan Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 47: China Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 48: China Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 49: Australia Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 50: Australia Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 51: South Korea Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 52: South Korea Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 53: India Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 54: India Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 55: Rest-of-Asia-Pacific Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 56: Rest-of-Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 57: Share of Key Developments, January 2019-June 2023
Figure 58: Number of Mergers and Acquisitions (by Company), January 2019-June 2023
Figure 59: Share of Synergistic Activities (by Company), January 2019-June 2023
Figure 60: Number of Business Expansions and Funding Activities (by Company), January 2019-June 2023
Figure 61: Number of Product Launches/Upgradations/Approvals (by Company), January 2019-June 2023
Figure 62: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 63: Emerging Infectious Disease Diagnostics Market, Total Number of Companies Profiled
Figure 64: CrisprBits: Overall Product Portfolio

List of Tables

Table 1: Some of the Key Developments By Companies Leveraging Emerging Technologies in Infectious Disease Diagnostics
Table 2: Key Product Offerings by Players in the Emerging Infectious Disease Diagnostics Market
Table 3: Key Questions Answered in the Report
Table 4: Some of the RT-LAMP Assays Developed during COVID-19
Table 5: Molecular Diagnostic Products for Infectious Diseases Under Development
Table 6: At-Home COVID-19 Kits Approved for Commercial Use by ICMR
Table 7: Disease Burden for Infectious Diseases (DALY), , Million, 2019
Table 8: Key Initiatives by Governments Globally
Table 9: Examples of International Research Consortiums for Managing Response to Infectious Diseases
Table 10: List of Infectious Disease Outbreaks (by Region and Year)
Table 11: Asia-Pacific Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 12: Emerging Infectious Disease Diagnostics Market, Key Active Players